Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections

Clin Infect Dis. 2020 Mar 3;70(6):1226-1229. doi: 10.1093/cid/ciz654.

Abstract

In a pilot randomized trial in persons with opioid use disorder hospitalized with injection-related infections, an innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinical and drug use outcomes to usual care (inpatient intravenous antibiotic completion) and shortened hospital length of stay by 23.5 days.

Clinical trials registration: NCT03048643.

Keywords: antibiotics; buprenorphine; endocarditis; injection-drug use; opioid-related disorders.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents* / therapeutic use
  • Buprenorphine* / therapeutic use
  • Humans
  • Opiate Substitution Treatment
  • Opioid-Related Disorders* / drug therapy
  • Outpatients

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Buprenorphine

Associated data

  • ClinicalTrials.gov/NCT03048643